热景生物
(688068)
| 流通市值：125.16亿 | | | 总市值：125.16亿 |
| 流通股本：9270.79万 | | | 总股本：9270.79万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 93,241,595.44 | 510,900,037.23 | 386,162,937.71 | 248,810,028.12 |
| 营业收入 | 93,241,595.44 | 510,900,037.23 | 386,162,937.71 | 248,810,028.12 |
| 二、营业总成本 | 130,399,057.32 | 611,500,124.43 | 444,863,278.09 | 295,455,665.46 |
| 营业成本 | 49,168,539.61 | 228,067,900.41 | 183,673,367.75 | 124,464,867.46 |
| 税金及附加 | 636,531.31 | 6,163,442.99 | 4,117,913.46 | 3,014,038.79 |
| 销售费用 | 43,441,584.85 | 191,570,764.78 | 129,084,145.72 | 90,903,061 |
| 管理费用 | 24,107,192.49 | 103,896,662.78 | 70,854,336.71 | 42,295,082.11 |
| 研发费用 | 20,426,393.23 | 113,311,176.16 | 77,198,837.52 | 49,646,684.94 |
| 财务费用 | -7,381,184.17 | -31,509,822.69 | -20,065,323.07 | -14,868,068.84 |
| 其中:利息费用 | - | 449,066.76 | - | 173,092.79 |
| 其中:利息收入 | 7,475,391.29 | 32,848,354.88 | 20,005,113.82 | 15,151,387.57 |
| 加:公允价值变动收益 | -23,053,551.7 | 2,493,695.02 | 19,700,082.57 | -2,867,291.23 |
| 加:投资收益 | 33,698,955.39 | -11,857,198.21 | -9,402,109.95 | 2,901,208.51 |
| 资产处置收益 | -1,182.67 | -1,632,972.55 | 1,162,986.74 | 284,632.87 |
| 资产减值损失(新) | -25,220.12 | -83,123,913.7 | -99,632.54 | -545,958.43 |
| 信用减值损失(新) | - | -1,018,888.62 | -2,121,326.21 | -4,039,056.53 |
| 其他收益 | 2,512,018.09 | 10,149,543.59 | 11,167,725.74 | 8,848,265.47 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -24,026,442.89 | -185,589,821.67 | -38,292,614.03 | -42,063,836.68 |
| 加:营业外收入 | 311,048.22 | 325,388.43 | 1,647,206.51 | 171,744.96 |
| 减:营业外支出 | 393,836.35 | 2,609,244.45 | 1,206,049.78 | 1,180,379.07 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -24,109,231.02 | -187,873,677.69 | -37,851,457.3 | -43,072,470.79 |
| 减:所得税费用 | 457,539.02 | 8,064,976.66 | 4,829,939.31 | 2,590,124.57 |
| 六、净利润 | -24,566,770.04 | -195,938,654.35 | -42,681,396.61 | -45,662,595.36 |
| 持续经营净利润 | -24,566,770.04 | -195,938,654.35 | -42,681,396.61 | -45,662,595.36 |
| 归属于母公司股东的净利润 | -24,008,215.62 | -191,004,566.74 | -40,638,579.96 | -43,467,813.74 |
| 少数股东损益 | -558,554.42 | -4,934,087.61 | -2,042,816.65 | -2,194,781.62 |
| (一)基本每股收益 | -0.26 | -2.12 | -0.44 | -0.47 |
| (二)稀释每股收益 | -0.26 | -2.12 | -0.44 | -0.47 |
| 八、其他综合收益 | 317,437.68 | 5,643,061.05 | 439,023.3 | -221,523.36 |
| 归属于母公司股东的其他综合收益 | 314,276.7 | 5,641,832.25 | 439,433.91 | -221,112.76 |
| 九、综合收益总额 | -24,249,332.36 | -190,295,593.3 | -42,242,373.31 | -45,884,118.72 |
| 归属于母公司股东的综合收益总额 | -23,693,938.92 | -185,362,734.49 | -40,199,146.05 | -43,688,926.5 |
| 归属于少数股东的综合收益总额 | -555,393.44 | -4,932,858.81 | -2,043,227.26 | -2,195,192.22 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |